A Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KM-819 in Healthy Older Adults and Participants With Parkinson's Disease
The goal of this study is to test KM-819 in halting or slowing the progression of Parkinson's disease.
The study evaluates the safety and tolerability of multiple ascending doses of KM-819 in healthy older adults and participants with Parkinson's disease.
100 Clinical Results associated with Fascinate Therapeutics , Inc.
0 Patents (Medical) associated with Fascinate Therapeutics , Inc.
100 Deals associated with Fascinate Therapeutics , Inc.
100 Translational Medicine associated with Fascinate Therapeutics , Inc.